A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Itraconazole; Verapamil

Criteria

Inclusion Criteria:

• Body mass index between 18 and 30 kg/m^2, inclusive

• Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram and routine laboratory assessments

• Adequate acoustic windows to enable accurate transthoracic echocardiographic assessment

• Left Ventricular Ejection Fraction (LVEF) ≥60% at screening and ≥55% prior to MYK-224 dosing

Exclusion Criteria:

• Any acute or chronic medical illness

• History of dizziness and/or recurrent headaches

• History of heart disease

Other protocol-defined inclusion/exclusion criteria apply